24.416.114.02378,760201820192020202118.816.815.387,72486,24180,71780,84913,20312,27615,16812,27313,9172022Initiatives in the fiscal year ended September 2023Key theme of strategyPlanning and creation of high-quality projectsDiversified licensing activitiesImplementation of R&D projects with an emphasis on quality and speedMain results•Two newly acquired candidate phase*1 projects; exclusive license agreement with Alchemedicine, Inc.for an ALDH2 (aldehyde dehydrogenase 2) activator, etc.•Two newly acquired projects in development phase*2 Signed an exclusive license agreement withNielsen BioSciences, Inc. for Candida albicans extract, a treatment for verruca vulgaris (commonwarts), etc.•Signed an exclusive license agreement with Journey Medical Corporation for hyperhidrosis treatmentglycopyrronum tosilate hydrate in South Korea, Taiwan, Hong Kong, Macau, and the 10 ASEANmember states•Steady progress in R&D•Promotion of global projects in collaboration with partners•Obtained approval for BEPIO Lotion (additional dosage form) for the treatment of acne vulgaris,Renail Gel for the treatment of pincer nails, and Amenalief Tablets (additional indication), ananti-herpes virus agentR&D expenses*1 Prior to early phase II studies in clinical development *2 After late phase II studies in clinical developmentMaruho Report 20233.Strategy for Value Creation Progress of the Medium-Term PlanR&D and Business DevelopmentR&D capabilities paving the way for new treatments in dermatologyMaruho researches and develops prescription drugs mainly used in dermatology using an approach that is closely in tune with patient needs.With the aim of creating novel drugs suited to global markets, we pursue optimal portfolio management that considers everything from development pipeline and R&D resources to market environment and unmet needs. We plan and execute a testing program with an eye toward promptness and enhanced value, focusing on the identification biomarkers linked to the appropriate use of drugs and acquisition of clinical and non-clinical data that contributes to appropriate use. Additionally, we are working on creating proprietary topical drug formulation technology. In addition to product development, we continue to plan and implement business strategies in new areas based on medical needs in new business fields and alliance strategies with partners with an eye toward maximizing the value of projects.* The pharmaceutical business includes Maruho’s medical devices business, self-care business, and Maruho Medical, Inc.’s medical devices business.Pharmaceutical business* net sales / R&D expenses / Ratio of R&D expenses to net salesPharmaceutical business net sales (Millions of yen)Ratio of R&D expenses to net sales (%)R&D expenses (Millions of yen)202386,29286,29221,034million yen21,034
元のページ ../index.html#24